Halozyme Therapeutics Announces Executive and Board Changes
Ticker: HALO · Form: 8-K · Filed: Dec 9, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Dec 9, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $10 million, $115.00, $130.00, $145.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: HALO
TL;DR
HALO board/exec shakeup, new comp plans announced.
AI Summary
On December 4, 2025, Halozyme Therapeutics, Inc. announced changes in its executive team and board of directors. The filing details the departure of certain officers and directors, the election of new directors, and updates to compensatory arrangements for key executives. Specific names and financial details of these arrangements are not provided in this summary section of the filing.
Why It Matters
Changes in leadership and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Executive and board changes, especially without detailed financial disclosures on compensation, introduce uncertainty about future strategy and leadership stability.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- December 4, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 12390 El Camino Real, San Diego, CA 92130 (address) — Principal business address
FAQ
What specific items are being reported under the 8-K filing?
The filing reports on the Departure of Directors or Certain Officers, Election of Directors, Appointment of Certain Officers, and Compensatory Arrangements of Certain Officers.
When was the earliest event reported in this filing?
The earliest event reported was on December 4, 2025.
What is the exact name of the registrant?
The exact name of the registrant is HALOZYME THERAPEUTICS, INC.
In which state was Halozyme Therapeutics, Inc. incorporated?
Halozyme Therapeutics, Inc. was incorporated in Delaware.
What is the principal business address of Halozyme Therapeutics, Inc.?
The principal business address is 12390 El Camino Real, San Diego, California 92130.
Filing Stats: 905 words · 4 min read · ~3 pages · Grade level 12.1 · Accepted 2025-12-09 16:45:01
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
- $10 million — lying a Monte Carlo valuation model) of $10 million. The number of shares of Company common
- $115.00 — d as described below) equals or exceeds $115.00; (ii) 100% of the target number of shar
- $130.00 — ompany's common stock equals or exceeds $130.00; (iii) 150% of the target number of sha
- $145.00 — ompany's common stock equals or exceeds $145.00; (iv) 200% of the target number of shar
- $170.00 — ompany's common stock equals or exceeds $170.00; and (v) no shares subject to the PSU G
- $115 — ompany's common stock never reaches the $115 level during the four-year performance
Filing Documents
- halo-20251204.htm (8-K) — 32KB
- halo-20251204_g1.jpg (GRAPHIC) — 15KB
- 0001159036-25-000070.txt ( ) — 173KB
- halo-20251204.xsd (EX-101.SCH) — 2KB
- halo-20251204_lab.xml (EX-101.LAB) — 21KB
- halo-20251204_pre.xml (EX-101.PRE) — 12KB
- halo-20251204_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc. (Registrant) Dated: December 9, 2025 By: /s/ Mark Snyder Mark Snyder Senior Vice President, General Counsel and Corporate Secretary